최적의 폐암 치료 전략 개발을 통한 폐암 환자 삶의 질 개선 및 생존율 향상 추구

2003년부터 고려대학교 구로병원 호흡기내과 임상강사를 시작한 이래로 흡연과 관련된 만성폐쇄성 폐질환 및 폐암 환자만을 특화하여 진료하고 치료해 온 노하우를 바탕으로 폐암 환자들에게 친근한 폐암치료 환경을 제공하고 폐암으로 인한 고통을 경감시키기 위한 치료 방법들을 모색해 옴.

폐암의 치료에 있어서 세포독성 항암제의 한계점을 극복하기 위해 종양 면역학에 관심을 갖고 2011년부터 2년간 미국 존스홉킨스 의대 병리과에서 종양백신을 이용한 면역치료 기법들에 대한 연구를 수행함. 그러한 종양 면역학적 지식들을 바탕으로 최근 폐암치료의 패러다임을 바꾸고 있는 면역항암치료제 (Immune checkpoint inhibitor)를 이용한 다향한 임상 연구에 참여하고 있다.

최근 폐암 신약을 이용한 글로벌 임상연구에 적극적으로 참여하고 있으며, 표적치료제를 이용한 연구자 주도 임상연구를 수행하고 있으며, 다양한 폐암 진단 및 치료와 관련된 바이오마커 발굴을 위한 연구를 수행하고 있다.

Education

• 박사 (2003-2006): 고려대학교 의학과
• 석사 (1998-2000): 고려대학교 의학과
• 학사 (1989-1995): 고려대학교 의학과

Professional Experiences

• 2015-현재 : 고려대학교 의학과 내과학교실 교수
• 2014-현재 : 고려대학교 구로병원 호흡기내과 분과장
• 2009- 2015: 고려대학교 의학과 내과학교실 부교수
• 2006- 2009: 고려대학교 의학과 내과학교실 조교수
• 2011- 2013: 미국 Johns Hopkins Medical Center Department of Pathology 연수

Membership

• Member of Korean Society of Internal Medicine
• Member of Korean Academy of Tuberculosis and Respiratory Disease
• Member of Korean Association for the Study of Lung Cancer
• Member of Asian Pacific Society of Respirology
• Member of American Association for Cancer Research
• Member of International Association for the Study of Lung Cancer


• 현 대한 내과학회 고시위원, 교육위원
• 현 대한 결핵및호흡기학회 간행위원, 법제·윤리위원
• 현 대한 폐암학회 학술위원

수상 경력

• 1996 Department of Internal Medicine, Korea University Medical Center: The best resident of the Year
• 2007 Korean Association for the Study of Lung Cancer : Outstanding Poster Award
• 2008 The Korean Lung Cancer Society : Outstanding Poster Award
• 2008 The Korean Lung Cancer Society : The best paper of the year
• 2009 European Multidisciplinary Conference in Thoracic Oncology (EMCTO) : Travel Award
• 2013 The Korean Journal of Internal Medicine : The outstanding paper of the year

• 1. Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein. Seo TS, Song MG, Kim JS, Choi CW, Seo JH, Oh SC, Kang EJ, Lee JK, Lee SY. J Vasc Access. 2017 Jul 14;18(4):345-351
• 2. A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients. Pamungkas AD, Medriano CA, Sim E, Lee S, Park YH. Mol Med Rep. 2017 Jun;15(6):4155-4161
• 3. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Lee SH, Choi SI, Lee JS, Kim CH, Jung WJ, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, In KH. Cancer Res Treat. 2017 Jan;49(1):141-149
• 4. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis. Kang EJ, Min KH, Hur GY, Lee SY, Shim JJ, Kang KH, Oh SC, Seo JH, Kim JS. Chemotherapy. 2016;61(1):41-50
• 5. Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis. Kang EJ, Lee SY, Kim HJ, Min KH, Hur GY, Shim JJ, Kang KH, Oh SC, Seo JH, Lee SY, Kim JS. Oncology. 2016;90(2):103-11
• 6. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, Lee KY, Lee SY. BMC Cancer. 2016 Aug 26
• 7. High resolution metabolomics to discriminate compounds in serum of male lung cancer patients in South Korea. Aryo D. Pamungkas, Changyoung Park, Sungyong Lee, Sun Ha Jee and Youngja H. Park. Respiratory Research 2016.17:100
• 8. The effect of an IκB-kinase-β(IKKβ) inhibitor on tobacco smoke-induced pulmonary inflammation. Choi SI, Lee SY, Jung WJ, Lee SH, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Lee MG. Exp Lung Res. 2016 May;42(4):182-9
• 9. Serum Procalcitonin for Differential Diagnosis of Acute Exacerbation and Bacterial Pneumonia in Patients with Interstitial Lung Disease. Sim JK, Oh JY, Lee EJ, Hur GY, Lee SH, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Min KH Am J Med Sci. 2016 May;351(5):499-505
• 10. Quercetin Enhances Chemosensitivity to Gemcitabine in Lung Cancer Cells by Inhibiting Heat Shock Protein 70 Expression. Lee SH, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Lee SY. Clin Lung Cancer. 2015 May 18
• 11. Association between interleukin-27 polymorphisms and pulmonary tuberculosis. Oh JY, Sim JK, Jung WJ, Min KH, Lee EJ, Hur GY, Lee SY, Lee SY, Kwon AM, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Lee SH. Int J Tuberc Lung Dis. 2015 Jun;19(6):702-8
• 12. Reactive oxygen species modulator 1 (Romo1) overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resection. Lee SH, Min JW, Lee JS, Kim CH, Yoo YD, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, In KH. Lung Cancer. 2015 Jan;87(1):45-52
• 13. Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. Kim HR, Lee JC, Kim YC, Kim KS, Oh IJ, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Ryu JS, Jang SH, Son JW, Lee JE, Kim SY, Kim HJ, Lee KY. Lung Cancer. 2014 Feb;83(2):252-8
• 14. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer. Lee SH, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, In KH. Lung Cancer. 2014 Aug;85(2):175-81
• 15. Increased expression of vascular endothelial growth factor and hypoxia inducible factor-1α in lung tissue of patients with chronic bronchitis. Lee SH, Lee SH, Kim CH, Yang KS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Lee SY. Clin Biochem. 2014 May;47(7-8):552-9
• 16. Effects of transglutaminase 2 inhibition on ventilator-induced lung injury. Suh IB, Yoon DW, Oh WO, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Lee SY, Shin C, Shim JJ, In KH, Kang KH, Kim JH. J Korean Med Sci. 2014 Apr;29(4):556-63
• 17. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion. Lee SH1, Lee EJ, Min KH, Hur GY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Lee SY. Clin Biochem. 2013 Oct;46(15):1484-8
• 18. Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer. Lee SH1, Suh IB, Lee EJ, Hur GY, Lee SY, Lee SY, Shin C, Shim JJ, In KH, Kang KH, Yoo SH, Kim JH. Yonsei Med J. 2013 Nov;54(6):1394-9
• 19. Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial. Lee SY, Park HS, Lee KY, Kim HJ, Jeon YJ, Jang TW, Lee KH, Kim YC, Kim KS, Oh IJ, Kim SY. Clin Lung Cancer. 2013 May;14(3):275-82.
• 20. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK, Choi CM, Yang SH, Kim YC, Lee YC, Kim SY, Jang SH, Lee JC, Lee KY. J Exp Clin Cancer Res. 2013 Aug 9;32(1):50
• 21. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. Lee SY, Huang Z, Kang TH, Soong RS, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, Wu TC. J Mol Med (Berl). 2013 May 29.
• 22. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother. Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, Hung CF, Wu TC. 2013 Jul;62(7):1175-85
• 23. The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer. Lee KJ, Lee EJ, Hur GY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH, Lee SY. Korean J Intern Med. 2013 Jul;28(4):449-55.
• 24. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH. Lung Cancer. 2013 Jul;81(1):102-8
• 25. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. Soong RS, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF. PLoS One. 2013;8(2):e56912.
• 26. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF, Wu TC. Cancer Res. 2013 Apr 15;73(8):2493-504
• 27. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion. Lee SH, Lee EJ, Min KH, Hur GY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Lee SY. Clin Biochem. 2013 Apr 6. pii: S0009-9120(13)00111-2.
• 28. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY. Lung Cancer. 2012 Mar;75(3):321-5.
• 29. Curious Case of Combined Small- and Squamous Cell Carcinoma. Lee SY, Shim JJ, Kang KH, Shin BK. J Clin Oncol. 2010 Dec 20.
• 30. Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance.LeeKJ,MoonJY,ChoiHK,KimHO,HurGY,JungKH,LeeSY,KimJH,ShinC,ShimJJ,InKH,YooSH,KangKH, Lee SY. Clin Exp Immunol. 2010 May 18.
• 31. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer.KimHO,ShimJJ,KangKH,ShinBK. Lee SY. J Thorac Oncol. 2010 Mar;5(3):401-2.
• 32. An anaphylactic reaction caused by levodropropizine.HurGY, Lee SY, Shim JJ, Park HS, Kang KH. Allergy. 2010 Mar;65(3):409-10.
• 33. Asthma-like symptoms are increased in the metabolic syndrome.LeeEJ,InKH,HaES,LeeKJ,HurGY,KangEH,JungKH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, Yoo SH. J Asthma. 2009 May;46(4):339-42.
• 34. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. J Immunother. 2009 Jan;32(1):22-8
• 35. Inflammatory and transcriptional roles of poly (ADP-ribose) polymerase in ventilator-induced lung injury.KimJH,SukMH,YoonDW,KimHY,JungKH,KangEH, Lee SY, Lee SY, Suh IB, Shin C, Shim JJ, In KH, Yoo SH, Kang KH. Crit Care. 2008;12(4):R108.
• 36. Aspiration pneumonia due to polyethylene glycol-electrolyte solution (Golytely) treated by bronchoalveolar lavage.HurGY, Lee SY, Shim JJ, In KH, Kang KH, Yoo SH. Respirology. 2008 Jan;13(1):152-4
• 37. Proteomic analysis of peripheral T-lymphocytes in patients with asthma.JeongHC, Lee SY, Lee EJ, Jung KH, Kang EH, Lee SY, Kim JH, Park EK, Lee SH, Uhm CS, Cho Y, Shin C, Shim JJ, Kim HK, In KH, Kang KH, Yoo SH. Chest. 2007 Aug;132(2):489-96.
• 38. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Lee SY, Kang EJ, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, In KH, Kang KH, Yoo SH, Shim JJ. RESPIRATORY MEDICINE. 100:503-11,2006
• 39. Successful removal after vascular embolization in a slowly engrowing mediastinal cavernous haemangioma: a case report. Lee SY, Lee JH, Kim JH, Shin C, In KH, Kang KH, Yoo SH, Shim JJ. RESPIROLOGY. 11:493-5,2006
• 40. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.Lee SY, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. LUNG CANCER. 51:297-301,2006
• 41. Peroxisome proliferator activated receptor-g (PPAR-g) inhibits Cigarette Smoke Solution-induced Mucin Production in human airway epithelial (NCI-H292) cells. Lee SY, Kang EJ, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, In KH, Kang KH, Yoo SH, Shim JJ. Am J Physiol Lung Cell Mol Physiol. 291:L84-90,2006
• 42. The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea.KimSJ,SukMH,ChoiHM,KimmKC,JungKH, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. Int J Tuberc Lung Dis. 2006 Dec;10(12):1393-8
• 43. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.JeongHC, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. LUNG CANCER. 2006 Sep;53(3):361-6
• 44. Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury.KimJH,SukMH,YoonDW,LeeSH,HurGY,JungKH,JeongHC, Lee SY, Lee SY, Suh IB, Shin C, Shim JJ, In KH, Yoo SH, Kang KH. Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L580-7.
• 45. A case of Extramedullary Plasmacytoma Arising from the Posterior Mediastinum. LeeSY, Kim JH, Shin JS, Shin C, In KH, Kang KH, Yoo SH. The Korean Journal of Internal Medicine. 20:173-176, 2005
• 46. Effects of matrix metalloproteinase inhibitor on LPS-induced goblet cell metaplasia.KimJH,LeeSY,BakSM,SuhIB,Lee SY, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. Am J Physiol Lung Cell Mol Physiol. 2004 Jul;287(1):L127-33.

Clinical Trials

Lung Cancer IIT, Phase III Completed

Phase III Multicenter Comparative Study Between Belotecan/Cisplatin and Etoposide/Cisplatin (COMBAT) in Patients with Previously Untreated, Extensive Stage Small Cell Lung Cancer

Lung Cancer IIT, Phase II Completed

Paclitaxel Loaded Polymeric Micelle (230 mg/m2)andCisplatin(60mg/m2)VersusPaclitaxel(175mg/m2)andCisplatin(60mg/m2)inAdvancedNon-SmallCellLungCancer:AMulticenterRandomizedPhaseIIBTrial

Lung Cancer SIT, Phase III Completed

A randomized Phase Ⅲ trial of comparing Pemetrexed Versus Pemetrexed combination INNOLAK as second-line treatment in patients with advanced Non-Small Cell Lung Cancer

Lung Cancer IIT, Phase IV Completed

A Phase IV, multicenter, non-randomized, open-labeled study to evaluate the efficacy of Gefitinib (IRESSA®)asasecond-linetherapyandtheroleofplasmabiomakersinNSCLCpatients

Lung Cancer SIT, Phase IV Completed

A Korean multicenter, randomized, double-blind, clinical trial to evaluate the efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in the first cycle of moderately emetogenic chemotherapies with broad range of tumor types.

Oncology SIT, Phase III Completed

A randomized, double-blind, double-dummy, parallel group, international multi-center study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer

Lung Cancer SIT, Phase II ongoing

A Phase II, Non-comparative, Open label, multi-center, international study of MEDI4736, in patients with locally advanced or metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) who have received at least two prior systemic regimens including on platinum-based therapy.

Lung Cancer SIT, Phase III ongoing

Randomized, multicenter, phase III, open-label study of alectinib versus pemetrexed or docetaxel in anaplastic lymphoma kinase-positive advanced nonsmall cell lung cancer patients previously treated with platinum-based chemotherapy and crizotinib

Lung Cancer SIT, Phase III ongoing

A phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet.

Lung Cancer SIT, Phase III ongoing

Open label, multinational, multicenter, real world treatment study of single agent AZD9291 for patients with advance/metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLS) who have received prior therapy with an EGFR tyrosine kinase inhibitor (EGFR-TKI).

Lung Cancer SIT, Phase III ongoing

A phase III randomized, open-label, multi-center, global study of MEDI4736 in combination with tremelimumab therapy versus standard of care platinum-based chemotherapy in first line treatment of patients with advanced or metastatic non small-cell lung cancer (NSCLC) (NEPTUNE).

Lung Cancer SIT, Phase III ongoing

A Multicenter, Randomzied, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in previously untreated patients with EGFR-mutation positive Metastatic non-small cell lung cancer.

Lung Cancer SIT, Phase III ongoing

Randomized, Open-Label Phase 3 Trial of Nivolumab + Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816)

Lung Cancer IIT, Phase II ongoing

A single-arm, open-label, multicenter, exploratory phase 2 study to evaluate the efficacy and safety of pemetrexed plus cisplatin as second-line treatment in patients with locally advanced or metastatic EGFR-mutation positive-NSCLC after EGFR-TKI as first-line treatment.

Lung Cancer IIT, Phase II ongoing

Retreatment with 1st generation EGFR TKIs in sensitizing EGFR mutation positive NSCLC patients who previously treated with EGFR TKI and cytotoxic chemotherapy

Lung Cancer SIT, Phase III ongoing

A Randomized, Open‐label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for High DLL3 expressing Small Cell Lung Cancer (SCLC) Subjects with First Relapse/Recurrence Following Front‐Line Platinum‐Based Chemotherapy (TAHOE).

Lung Cancer SIT, Phase III ongoing

A Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First‐Line Platinum‐Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU).

Research Topic

1) 종양 면역을 이용한 폐암 치료 전략개발 및 바이오마커 탐색

다수 종양항원 백신을 이용한 항암효과 증진을 위한 치료 전략 개발을 위한 실험을 진행하고 있으며, 또한 최근 면역항암제 (Immune checkpoint inhibitor)를 이용한 폐암환자 치료에서 면역항암제의 Predictive biomarker를 탐색하는 연구를 진행하고 있음.

2) 폐암환자에서 적절한 표적치료제의 선택과 내성기전의 연구

상피세포성장인자 수용체 변이 양성 환자에서 상피세포성장인자 수용체 억제제의 retreatment를 통한 폐암환자의 생존율 향상 및 T790M 내성 유전자 발현에 관한 임상 연구를 진행하고 있음.

의학과 호흡기학

• 폐기능검사 및 동맥혈 가스검사의 해석
• 폐암

응급의학과

• 호흡기응급

호흡기내과학 임상실습 책임 교수

연구원

• 심은정

Clinical Research Coordinator

• 정주애 RN
• 박정훈 RN